Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

Post-hoc analysis (n=326) found inhaled treprostinil was associated with an improvement in FVC of 1.8% vs placebo at both 8 and 16 weeks (both p<0.05). Subgroup analysis found the improvement was most evident in those with idiopathic interstitial pneumonia.

Source:

The Lancet Respiratory Medicine